Amgen Scoffs At Roche Proposal In EPO Patent Battle

Law360, New York (February 21, 2008, 12:00 AM EST) -- Amgen Inc. reiterated its desire for a permanent injunction barring F. Hoffman-La Roche Ltd.'s anemia treatment Mircera from the U.S. market, in response to the Swiss company's proposal to make the peg-EPO product available to patients in America and pay Amgen a 20% royalty on Mircera's U.S. sales.

Amgen filed a brief on Tuesday comparing Roche to a “snake-oil salesman” and arguing that U.S. District Judge William G. Young should issue an injunction barring Roche from selling any peg-EPO product in the U.S. for the term...
To view the full article, register now.